DataMeds AI and Datavault AI have amended their agreement to expand the licensing of Datavault AI's PharmacyChain blockchain technology beyond pharmaceutical distribution to include all commercial healthcare, healthspan, and wellness applications. This broadens the potential market for their integrated solutions, indicating a strategic move to leverage blockchain across a wider range of health-related sectors.
DataMeds AI and Datavault AI have expanded their existing definitive agreement, allowing DataMeds AI to license Datavault AI's PharmacyChain blockchain technology for a much wider array of applications. Previously limited to pharmaceutical distribution, the new agreement now covers 'all unencumbered commercial healthcare, healthspan and wellness applications' of Datavault AI's intellectual property. This is a positive development for both companies as it significantly increases the total addressable market for their integrated AI and blockchain solutions. In the short term, this could lead to increased investor interest due to the expanded growth potential. Long-term, it positions both companies to capture a larger share of the evolving digital health and wellness market, potentially driving revenue growth and market penetration. The key opportunity for traders lies in the potential for increased adoption and monetization of their blockchain-enabled platforms across diverse healthcare verticals.